ONK Therapeutics

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Developer of an artificial intelligence-enabled platform designed to advance synthetic lethal oncology. The company's platform identifies novel synthetic lethal targets and biomarkers and develops small-molecule therapeutic drug candidates, enabling clients to discover and develop treatments for cancer.

Developer of novel drug designed for doctors to treat neurodegenerative diseases. The company develops treatments that modulate mitophagy and autophagy by leveraging an understanding of critical neural pathways to discover and develop novel small molecules that will restore cellular balance and target lysosomes to modulate and restore their activity to prevent neurodegenerative diseases, enabling physicians to improve the lives of patients suffering from a range of neurodegenerative diseases and senescence.